US Stock MarketDetailed Quotes

CTNM Contineum Therapeutics

Watchlist
  • 7.730
  • +0.040+0.52%
Close Feb 14 16:00 ET
  • 7.690
  • -0.040-0.52%
Post 17:27 ET
199.26MMarket Cap-6.88P/E (TTM)

About Contineum Therapeutics Company

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Company Profile

SymbolCTNM
Company NameContineum Therapeutics
Listing DateApr 5, 2024
Issue Price16.00
Founded2017
CEOMr. Carmine Stengone
MarketNASDAQ
Employees31
Fiscal Year Ends12-31
Address3565 General Atomics Court,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-333-5280
Websitehttp://www.contineum-tx.com

Company Executives

  • Name
  • Position
  • Salary
  • Carmine Stengone
  • Chief Executive Officer, President and Chairman of the Board
  • 2.32M
  • Stephen L. Huhn, M.D.
  • Chief Medical Officer and Senior Vice President, Clinical Development
  • --
  • Daniel S. Lorrain, PhD
  • Chief Science Officer
  • 1.79M
  • Peter T. Slover
  • Chief Financial Officer and Principal Accounting Officer
  • 1.03M
  • Olivia C. Ware, M.B.A.
  • Independent Director
  • --
  • Lori Lyons-Williams
  • Independent Director
  • 25.00K
  • Evert B. Schimmelpennink
  • Independent Director
  • 23.82K
  • Dr. Todd C. Brady, M.D.,PhD
  • Independent Director
  • --
  • Sarah Boyce
  • Independent Director
  • --
  • Troy A. Ignelzi
  • Independent Director
  • --

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!